Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: A pilot study

Journal of Clinical Psychiatry

Volumn 63, Issue 11, 2002, Pages 972-980

  Sjögren, Magnus J C ^a,b   Hellström, Per T O ^a   Jonsson, Michael A G ^a   Runnerstam, Magnus ^a   Silander, Hans C son ^a   Ben Menachem, Elinor ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HEMATOMA; HOARSENESS; HUMAN; LUMBAR PUNCTURE; MALE; MINI MENTAL STATE EXAMINATION; MOOD; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PULSE GENERATOR; QUALITY OF LIFE; SAFETY; SYNCOPE; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

EID: 0036854306     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1103     Document Type: Article

References (57)

1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA 1989;262:2551-2556
2. Wimo A, Jönsson L. Demenssjukdomamas samhällskostnader. Äldreuppdraget 2000:14. Stockholm, Sweden: Socialstyrelsen; 2000
3. Lippa CF. Familial Alzheimer's disease: Genetic influences on the disease process. Int J Mol Med 1999;4:529-536
4. Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203
5. Bryant J, Clegg A, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review. Health Technol Assess 2001;5:1-137
6. Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32-42
7. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-638
8. Baily P, Bremer F. A sensory cortical representation of the vagus nerve. J Neurophysiol 1938;405-412
9. MacLean P. Psychosomatic disease and the 'visceral brain': Recent developments bearing on the Papez theory of emotion. Psychosom Med 1949;11:338-353
10. Dell P, Olson R. Projections (secondaires) mesencephaliques, diencephaliques, et amygdaliennes des afferentes viscerales vagales. C R Soc Biol (Paris) 1951b;145:1088-1091
11. MacLean PD. The Triune Brain in Evolution: Role in Paleocerebral Functions. New York, NY: Plenum Press; 1990
12. Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia 1992;33:1005-1012
13. Penry JK, Dean JC. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: Preliminary results. Epilepsia 1990;31(2 suppl):S40-S43
14. Rutecki P. Anatomical, physiological, and theoretical basis for the antiepileptic effect of vagus nerve stimulation. Epilepsia 1990;31(2, suppl):S1-S6
15. Clarke BM, Upton AR, Griffin HM. Cognitive motor function after electrical stimulation of the vagus nerve. Pacing Clin Electrophysiol 1992;15:1603-1607
16. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: A randomized active-control trial. Neurology 1998;51:48-55
17. Clark KB, Krahl SE, Smith DC, et al. Post-training unilateral vagal stimulation enhances retention performance in the rat. Neurobiol Learn Mem 1995;63:213-216
18. Clark KB, Naritoku DK, Smith DC, et al. Enhanced recognition memory following vagus nerve stimulation in human subjects. Nat Neurosci 1999;2:94-98
19. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study. Biol Psychiatry 2000;47:276-286
20. Sackeim HA, Keilp JG, Rush AJ, et al. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:53-62
21. Ben-Menachem E, Hamberger A, Hedner T, et al. Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epilepsy Res 1995;20:221-227
22. Walker BR, Easton A, Gale K. Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius. Epilepsia 1999;40:1051-1057
23. Krahl SE, Clark KB, Smith DC, et al. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998;39:709-714
24. Gottfries CG. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia [review]. J Neural Transm Suppl 1990;30:33-43
25. Sjögren M, Minthon L, Passant U, et al. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer disease. Neurobiol Aging 1998;19:379-384
26. Blennow K, Wallin A, Gottfries CG, et al. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm Park Dis Dement Sect 1993;5:5-15
27. Henry TR, Bakay RA, Votaw JR, et al. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy, 1: Acute effects at high and low levels of stimulation. Epilepsia 1998;39:983-990
28. Sjögren M, Gustafson L, Wikkelso C, et al. Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior to posterior rCBF-SPET ratio. Dement Geriatr Cogn Disord 2000;11:275-285
29. Waldemar G, Bruhn P, Kristensen M, et al. Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: A [99mTc]-d,1-HMPAO SPECT study. J Neurol Neurosurg Psychiatry 1994;57:285-295
30. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington. DC: American Psychiatric Association; 1994
32. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Geneva, Switzerland: World Health Organization; 1992
33. Wallin A, Brun A, Gustafson L. Swedish consensus on dementia diseases. Acta Neurol Scand 1994;90:8-18
34. George MS, Sackeim HA, Rush AJ, et al. Vagus nerve stimulation: A new tool for brain research and therapy. Biol Psychiatry 2000;47:287-295
35. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 1988;24:627-628
36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
37. Gottfries CG, Brane G, Gullberg B, et al. A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982;1:311-330
38. Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321
39. Dahlke F, Lohaus A, Gutzmann H. Reliability and clinical concepts underlying global judgments in dementia: Implications for clinical research. Psychopharmacol Bull 1992;28:425-432
40. Montgomery SA, Smeyatsky N, de Ruiter M, et al. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand Suppl 1985;320:38-42
41. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 1996;26:477-486
42. Ware JE, Sherboume CD. The MOS 36-Item Short-Form Health Survey (SF-36), 1: Conceptual framework and item selection. Med Care 1992;30:473-481
43. Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:69-77
44. Rogers SL, Farlow MR, Doody RS, et al, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145
45. Raskind MA, Peskind ER, Wessel T, et al, and the Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268
46. Wilcock GK, Lilienfeld S, Gaens E, for the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ 2000;321:1445-1449
47. Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-241
48. Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995;22:53-62
49. Krahl SE, Browning RA, Clark KB, et al. Possible mechanism of the seizure attenuating effects of vagus nerve stimulation [abstract]. Soc Neurosci Abstr 1994;20:1453
50. Krahl SE, Clark KB, Smith DC, et al. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998;39:709-714
51. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 1982;32:164-168
52. Matthews KL, Chen CPL-H, Esiri MM, et al. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 2002;51:407-416
53. Dringenberg HC. Alzheimer's disease: More than a 'cholinergic disorder' - Evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 2000;115:235-249
54. Gavrilyuk V, Dello Russo C, Heneka MT, et al. Norepinephrine increases IkappaBalpha expression in astrocytes. J Biol Chem 2002;227:29662-29668
55. Heneka MT, Galea E, Gavrilyuk V, et al. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: Implications for Alzheimer's disease. J Neurosci 2002;22:2434-2442
56. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: Efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001;25:713-728
57. Harden CL, Pulver MC, Ravdin LD, et al. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 2000;1:93-99